Pictet Asset Management
CLDX icon

Pictet Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Pictet Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$34.1M Sell
917,408
-6,288
-0.7% -$203K 0.03% 406
2026
Q1 		$29.3M Sell
923,696
-44,920
-5% -$1.22M 0.03% 416
2025
Q4 		$26.3M Sell
968,616
-243,374
-20% -$6.41M 0.03% 462
2025
Q3 		$31.4M Sell
1,211,990
-88,339
-7% -$2.05M 0.03% 423
2025
Q2 		$26.5M Buy
1,300,329
+342,535
+36% +$6.67M 0.03% 437
2025
Q1 		$17.4M Sell
957,794
-132,379
-12% -$2.96M 0.02% 531
2024
Q4 		$27.5M Sell
1,090,173
-48,273
-4% -$1.31M 0.03% 417
2024
Q3 		$38.7M Sell
1,138,446
-245,234
-18% -$9.34M 0.04% 339
2024
Q2 		$51.2M Sell
1,383,680
-111,275
-7% -$4.2M 0.06% 278
2024
Q1 		$62.7M Sell
1,494,955
-730,493
-33% -$30M 0.07% 269
2023
Q4 		$88.3M Buy
2,225,448
+374,478
+20% +$11M 0.1% 217
2023
Q3 		$50.9M Buy
+1,850,970
New +$58M 0.06% 284

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pictet Asset Management's CLDX Position: Q2 2026 in Review

Pictet Asset Management reduced its Celldex Therapeutics (CLDX) stake by 0.68% in Q2 2026, selling an estimated $203K and leaving 917,408 shares worth $34.1M. The position accounts for 0.03% of the portfolio, ranked #406.

Pictet Asset Management first reported a position in CLDX in Q3 2023 and has held it in 12 quarters since. The position peaked at $88.3M in Q4 2023. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Pictet Asset Management held 917,408 shares of Celldex Therapeutics worth $34.1M as of Q2 2026.
  • Pictet Asset Management sold 6,288 Celldex Therapeutics shares in Q2 2026, an estimated $203K.
  • Celldex Therapeutics made up 0.03% of Pictet Asset Management's portfolio in Q2 2026, its #406 holding.
  • Pictet Asset Management first reported a position in Celldex Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Pictet Asset Management's Celldex Therapeutics position peaked at $88.3M in Q4 2023.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Pictet Asset Management's 13F filing for Q2 2026, filed 30 Jul 2026.